Asuragen, Inc. Receives Notice of Patent Allowance for Broad Diagnostic Application of miR-21 in Cancer
Published: Oct 08, 2013
AUSTIN, Texas--(BUSINESS WIRE)--Asuragen, Inc., a molecular diagnostic company using genomics to drive better patient management, announced today that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 12/890,398 with claims covering the detection of miR-21 across all cancers and for all sample types.
Help employers find you! Check out all the jobs and post your resume.